```
in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:09:21 ON 08 SEP 2010

=> le reg
LE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 14:09:32 ON 08 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    7 SEP 2010  HIGHEST RN 1240243-66-6
DICTIONARY FILE UPDATES:   7 SEP 2010  HIGHEST RN 1240243-66-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10580480.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss
SAMPLE SEARCH INITIATED 14:10:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1819 TO ITERATE

100.0% PROCESSED     1819 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        33822 TO    38938
PROJECTED ANSWERS:               3 TO      163

L2            3 SEA SSS SAM L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.49       0.71

FILE 'CAPLUS' ENTERED AT 14:10:10 ON 08 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 8 Sep 2010 VOL 153 ISS 11
FILE LAST UPDATED: 7 Sep 2010 (20100907/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 1 L2

=> d ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 5.81 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:523234 CAPLUS
DOCUMENT NUMBER: 143:59339
TITLE: Preparation of diamine and iminodiacetic acid hydroxamic acid derivatives as histone deacetylase inhibitors useful against cancer and other diseases
INVENTOR(S): Miller, Thomas A.; Witter, David J.; Belvedere, Sandro
PATENT ASSIGNEE(S): Aton Pharma, Inc., USA
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053610	A2	20050616	WO 2004-US39221	20041123
WO 2005053610	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004294930	A2	20050616	AU 2004-294930	20041123
AU 2004294930	A1	20050616		
CA 2547356	A1	20050616	CA 2004-2547356	20041123

EP 1694329	A2	20060830	EP 2004-811866		20041123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1905881	A	20070131	CN 2004-80040991		20041123
JP 2007512367	T	20070517	JP 2006-541622		20041123
IN 2006DN03110	A	20070824	IN 2006-DN3110		20060531
US 20090023718	A1	20090122	US 2008-580480		20080214
PRIORITY APPLN. INFO.:			US 2003-525333P	P	20031126
			WO 2004-US39221	W	20041123

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:59339; MARPAT 143:59339

AB The present invention relates to a novel class of hydroxamic acid derivs. having a diamine or iminodiacetic acid backbone (1: (R1(HNC(O))p1CH2)(R2(HNC(O))p2CH2)N(C(O))m(CH2)nC(O)NHOH; n = 2-8; m = 0-1; p1 and p2 = 0 or 1; R1 and R2 = an (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when p1 and p2 are both 0, R1 and R2 together with the -CH2NCH2- group to which they are attached can also be a N-containing heterocyclic ring; or when at least one of p1 or p2 is not 0, R1 or R2 or both can also = H or alkyl; e.g. 6-[bis[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]amino]hexanoic acid hydroxyamide (2)). The hydroxamic acid compds. can be used to treat cancer. The hydroxamic acid compds. can also inhibit histone deacetylase (HDAC) and are suitable for use in selectively including terminal differentiation, arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, 1 are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. Compds. 1 are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compns. comprising the hydroxamic acid derivs., and safe, dosing regimens of these pharmaceutical compns., which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivs. in vivo. Although the methods of preparation are not claimed, example prepns. and/or characterization data for .apprx.60 1 are included. For example, 2 was prepared by coupling of 6-[N,N-bis(carboxymethyl)amino]hexanoic acid Me ester hydrochloride with N-phenylpiperazine using EDCI (74 %) followed by conversion of the Me ester to the hydroxamic acid using NH2OH (88 %). Results of HDAC inhibition by .apprx.80 examples of 1 are tabulated.

IT 853954-60-6P, Octanedioic acid N,N-bis[(cyclohexylcarbamoyl)methyl]amide hydroxyamide 853954-73-1P, Heptanedioic acid N-[(cyclohexylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide hydroxyamide 853954-79-7P, Heptanedioic acid N,N-bis[(2-phenoxyphenylcarbamoyl)methyl]amide hydroxyamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of diamine and iminodiacetic acid hydroxamic acid derivs. as histone deacetylase inhibitors useful against cancer and other diseases)

RN 853954-60-6 CAPLUS

CN Octanediamide, N1,N1-bis[2-(cyclohexylamino)-2-oxoethyl]-N8-hydroxy- (CA INDEX NAME)



RN 853954-73-1 CAPLUS
CN Heptanediamide, N1-[2-(cyclohexylamino)-2-oxoethyl]-N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]- (CA INDEX NAME)



RN 853954-79-7 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.81	7.52
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.85	-0.85

FILE 'REGISTRY' ENTERED AT 14:11:20 ON 08 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2010 HIGHEST RN 1240243-66-6
DICTIONARY FILE UPDATES: 7 SEP 2010 HIGHEST RN 1240243-66-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l1 sss full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 14:11:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 35574 TO ITERATE

100.0% PROCESSED 35574 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.02

L4 39 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	191.54	199.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'CAPLUS' ENTERED AT 14:11:40 ON 08 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 8 Sep 2010 VOL 153 ISS 11
FILE LAST UPDATED: 7 Sep 2010 (20100907/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4
L5 2 L4

=> d 1-2 ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 11.62 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:666074 CAPLUS
DOCUMENT NUMBER: 151:520134
TITLE: Pharmacophore identification of hydroxamate HDAC 1 inhibitors
AUTHOR(S): Yu, Liqin; Liu, Fei; Chen, Yadong; You, Qidong
CORPORATE SOURCE: Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, Jiangsu, 210009, Peop. Rep. China
SOURCE: Chinese Journal of Chemistry (2009), 27(3), 557-564
CODEN: CJOCEV; ISSN: 1001-604X
PUBLISHER: Shanghai Institute of Organic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A three-dimensional pharmacophore model was established based on 24 hydroxamate histone deacetylase (HDAC) inhibitors by HypoGen algorithm embedded in Catalyst software. The best pharmacophore hypothesis (Hypo1), consisting of four chemical features (one hydrogen-bond acceptor, one aromatic ring and two hydrophobic groups), has a correlation coefficient of 0.946. The Hypo1 was also validated by a test set consisting of 20 other compds. Compared with the prior studies towards HDAC inhibitors the detailed chemical features of the "CAP" region in the reported HDAC inhibitors were for the first time depicted, which would be helpful in the further designing of novel HDAC inhibitors.
IT 853954-78-6 853954-80-0 853954-87-7
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three-dimensional pharmacophore model was developed based on hydroxamate deacetylase 1 inhibitors by HypoGen algorithm embedded in catalyst software, suggests that branched cap structure of HDAC inhibitors strengthen interaction to HDAC 1)
RN 853954-78-6 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(trifluoromethyl)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-80-0 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[[4-(4-morpholinyl)phenyl]amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-87-7 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[(6-methoxy-2-benzothiazolyl)amino]-2-oxoethyl]- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:523234 CAPLUS
DOCUMENT NUMBER: 143:59339
TITLE: Preparation of diamine and iminodiacetic acid hydroxamic acid derivatives as histone deacetylase inhibitors useful against cancer and other diseases
INVENTOR(S): Miller, Thomas A.; Witter, David J.; Belvedere, Sandro
PATENT ASSIGNEE(S): Aton Pharma, Inc., USA
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005053610	A2	20050616	WO 2004-US39221		20041123
WO 2005053610	A3	20051222			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004294930	A2	20050616	AU 2004-294930		20041123
AU 2004294930	A1	20050616			
CA 2547356	A1	20050616	CA 2004-2547356		20041123
EP 1694329	A2	20060830	EP 2004-811866		20041123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1905881	A	20070131	CN 2004-80040991		20041123
JP 2007512367	T	20070517	JP 2006-541622		20041123
IN 2006DN03110	A	20070824	IN 2006-DN3110		20060531
US 20090023718	A1	20090122	US 2008-580480		20080214
PRIORITY APPLN. INFO.:			US 2003-525333P	P	20031126
			WO 2004-US39221	W	20041123

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:59339; MARPAT 143:59339

AB The present invention relates to a novel class of hydroxamic acid derivs. having a diamine or iminodiacetic acid backbone (1: (R1(HNC(O))p1CH2)(R2(HNC(O))p2CH2)N(C(O))m(CH2)nC(O)NHOH; n = 2-8; m = 0-1; p1 and p2 = 0 or 1; R1 and R2 = an (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when p1 and p2 are both 0, R1 and R2 together with the -CH2NCH2- group to which they are attached can also be a N-containing heterocyclic ring; or when at least one of p1 or p2 is not 0, R1 or R2 or both can also = H or alkyl; e.g. 6-[bis[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]amino]hexanoic acid hydroxyamide (2)). The hydroxamic acid compds. can be used to treat cancer. The hydroxamic acid compds. can also inhibit histone deacetylase (HDAC) and are suitable for use in selectively including terminal differentiation, arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, 1 are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. Compds. 1 are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compns. comprising the hydroxamic acid derivs., and safe, dosing regimens of these pharmaceutical compns., which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivs. in vivo. Although the methods of preparation are not claimed, example prepns. and/or

characterization data for .apprx.60 1 are included. For example, 2 was prepared by coupling of 6-[N,N-bis(carboxymethyl)amino]hexanoic acid Me ester hydrochloride with N-phenylpiperazine using EDCI (74 %) followed by conversion of the Me ester to the hydroxamic acid using NH2OH (88 %). Results of HDAC inhibition by .apprx.80 examples of 1 are tabulated.

IT 853954-53-7P, Octanedioic acid
N,N-bis[(quinolin-8-ylcarbamoyl)methyl]amide hydroxyamide
853954-55-9P, Hexanedioic acid
N,N-bis[(quinolin-8-ylcarbamoyl)methyl]amide hydroxyamide
853954-56-0P, Heptanedioic acid
N,N-bis[(quinolin-8-ylcarbamoyl)methyl]amide hydroxyamide
853954-57-1P, Heptanedioic acid
N,N-bis[(phenylcarbamoyl)methyl]amide hydroxyamide 853954-58-2P
, Octanedioic acid N,N-bis[(benzylcarbamoyl)methyl]amide hydroxyamide
853954-59-3P, Octanedioic acid
N,N-bis[(phenethylcarbamoyl)methyl]amide hydroxyamide
853954-60-6P, Octanedioic acid
N,N-bis[(cyclohexylcarbamoyl)methyl]amide hydroxyamide
853954-61-7P, Octanedioic acid
N,N-bis[(4-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide
853954-62-8P, Octanedioic acid
N,N-bis[(3-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide
853954-63-9P, Octanedioic acid
N,N-bis[(quinolin-6-ylcarbamoyl)methyl]amide hydroxyamide
853954-64-0P, Heptanedioic acid
N,N-bis[(benzylcarbamoyl)methyl]amide hydroxyamide 853954-65-1P
, Heptanedioic acid N,N-bis[(phenethylcarbamoyl)methyl]amide hydroxyamide
853954-66-2P, Heptanedioic acid
N,N-bis[(cyclohexylcarbamoyl)methyl]amide hydroxyamide
853954-67-3P, Heptanedioic acid
N,N-bis[(4-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide
853954-68-4P, Heptanedioic acid
N,N-bis[(3-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide
853954-69-5P, Heptanedioic acid
N,N-bis[[(benzothiazol-2-yl)carbamoyl]methyl]amide hydroxyamide
853954-70-8P, Heptanedioic acid
N,N-bis[(quinolin-6-ylcarbamoyl)methyl]amide hydroxyamide
853954-71-9P, Heptanedioic acid
N-[(benzylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide hydroxyamide
853954-72-0P, Heptanedioic acid hydroxyamide
N-[(phenethylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide
853954-73-1P, Heptanedioic acid
N-[(cyclohexylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide
hydroxyamide 853954-74-2P, Heptanedioic acid hydroxyamide
N-[(phenylcarbamoyl)methyl]-N-[(quinolin-8-ylcarbamoyl)methyl]amide
853954-75-3P, Heptanedioic acid
N,N-bis[(4-fluorophenylcarbamoyl)methyl]amide hydroxyamide
853954-76-4P, Heptanedioic acid
N,N-bis[[(2,3-dihydrobenzo[1,4]dioxin-6-yl)carbamoyl]methyl]amide
hydroxyamide 853954-77-5P, Heptanedioic acid
N,N-bis[(1H-indazol-5-ylcarbamoyl)methyl]amide hydroxyamide
853954-78-6P, Heptanedioic acid
N,N-bis[[(4-trifluoromethylphenyl)carbamoyl]methyl]amide hydroxyamide
853954-79-7P, Heptanedioic acid
N,N-bis[(2-phenoxyphenylcarbamoyl)methyl]amide hydroxyamide
853954-80-0P, Heptanedioic acid

N,N-bis[[[4-(morpholin-4-yl)phenyl]carbamoyl]methyl]amide hydroxyamide
853954-81-1P, Heptanedioic acid
N,N-bis[[[4-[(4-tolylsulfonyl)amino]phenyl]carbamoyl]methyl]amide
hydroxyamide 853954-82-2P, Heptanedioic acid
N,N-bis[(benzodioxol-5-ylcarbamoyl)methyl]amide hydroxyamide
853954-83-3P, Heptanedioic acid
N,N-bis[(3-phenoxyphenylcarbamoyl)methyl]amide hydroxyamide
853954-84-4P, Heptanedioic acid
N,N-bis[(9H-fluoren-2-ylcarbamoyl)methyl]amide hydroxyamide
853954-85-5P, Heptanedioic acid
N,N-bis[(4-tert-butylphenylcarbamoyl)methyl]amide hydroxyamide
853954-86-6P, Heptanedioic acid
N,N-bis[[[2-(1H-indol-3-yl)ethyl]carbamoyl]methyl]amide hydroxyamide
853954-87-7P, Heptanedioic acid
N,N-bis[(6-methoxybenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide
853954-88-8P, Heptanedioic acid
N,N-bis[(6-chlorobenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide
853954-89-9P, Heptanedioic acid
N,N-bis[(4-methylbenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide
853954-90-2P, Heptanedioic acid
N,N-bis[(indan-1-ylcarbamoyl)methyl]amide hydroxyamide
853954-91-3P, Heptanedioic acid
N,N-bis[[(1-methyl-1H-benzimidazol-2-yl)carbamoyl]methyl]amide
hydroxyamide 853954-92-4P, Heptanedioic acid
N,N-bis[(6-fluorobenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of diamine and iminodiacetic acid hydroxamic acid derivs. as histone deacetylase inhibitors useful against cancer and other diseases)

RN 853954-53-7 CAPLUS
CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-(8-quinolinylamino)ethyl]-
(CA INDEX NAME)



RN 853954-55-9 CAPLUS
CN Hexanediamide, N6-hydroxy-N1,N1-bis[2-oxo-2-(8-quinolinylamino)ethyl]-
(CA INDEX NAME)



RN 853954-56-0 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-(8-quinolinylamino)ethyl]- (CA INDEX NAME)



RN 853954-57-1 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-(phenylamino)ethyl]- (CA INDEX NAME)



RN 853954-58-2 CAPLUS
CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[(phenylmethyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-59-3 CAPLUS
CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[(2-phenylethyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-60-6 CAPLUS
CN Octanediamide, N1,N1-bis[2-(cyclohexylamino)-2-oxoethyl]-N8-hydroxy- (CA INDEX NAME)



RN 853954-61-7 CAPLUS
CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[[4-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-62-8 CAPLUS
CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[[3-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-63-9 CAPLUS
CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-(6-quinolinylamino)ethyl]- (CA INDEX NAME)



RN 853954-64-0 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(phenylmethyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-65-1 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(2-phenylethyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-66-2 CAPLUS
CN Heptanediamide, N1,N1-bis[2-(cyclohexylamino)-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-67-3 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-68-4 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[3-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-69-5 CAPLUS
CN Heptanediamide, N1,N1-bis[2-(2-benzothiazolylamino)-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-70-8 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-(6-quinolinylamino)ethyl]-

(CA INDEX NAME)



RN 853954-71-9 CAPLUS
CN Heptanediamide, N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]-N1-[2-oxo-2-[(phenylmethyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-72-0 CAPLUS
CN Heptanediamide, N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]-N1-[2-oxo-2-[(2-phenylethyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-73-1 CAPLUS
CN Heptanediamide, N1-[2-(cyclohexylamino)-2-oxoethyl]-N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]- (CA INDEX NAME)



RN 853954-74-2 CAPLUS

CN Heptanediamide, N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]-N1-[2-oxo-2-(8-quinolinylamino)ethyl]- (CA INDEX NAME)



RN 853954-75-3 CAPLUS
CN Heptanediamide, N1,N1-bis[2-[(4-fluorophenyl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-76-4 CAPLUS
CN Heptanediamide, N1,N1-bis[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-77-5 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-(1H-indazol-5-ylamino)-2-oxoethyl]- (CA INDEX NAME)



RN 853954-78-6 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(trifluoromethyl)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-79-7 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-80-0 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[[4-(4-morpholinyl)phenyl]amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-81-1 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[[4-[[(4-methylphenyl)sulfonyl]amino]phenyl]amino]-2-oxoethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 853954-82-2 CAPLUS
CN Heptanediamide, N1,N1-bis[2-(1,3-benzodioxol-5-ylamino)-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-83-3 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(3-phenoxyphenyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-84-4 CAPLUS
CN Heptanediamide, N1,N1-bis[2-(9H-fluoren-2-ylamino)-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-85-5 CAPLUS
CN Heptanediamide, N1,N1-bis[2-[[4-(1,1-dimethylethyl)phenyl]amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-86-6 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[[2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-87-7 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[(6-methoxy-2-benzothiazolyl)amino]-

2-oxoethyl]- (CA INDEX NAME)



RN 853954-88-8 CAPLUS
CN Heptanediamide, N1,N1-bis[2-[(6-chloro-2-benzothiazolyl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-89-9 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[(4-methyl-2-benzothiazolyl)amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-90-2 CAPLUS
CN Heptanediamide, N1,N1-bis[2-[(2,3-dihydro-1H-inden-1-yl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-91-3 CAPLUS
CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[(1-methyl-1H-benzimidazol-2-yl)amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-92-4 CAPLUS
CN Heptanediamide, N1,N1-bis[2-[(6-fluoro-2-benzothiazolyl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)